Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where can I change my password on Ihub. My account has been breeched
Where can I change my password on Ihub?
Looks like the MM short share signal just went by. Was there for awhile. Im' holding
News: I knew something was up
Image
First-in-human study update: Study open for enrolment
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense™ HER2 breast cancer Phase I first-in-human study.
Dr Jane Fox, the current Director of Breast Services at Monash Health, which encompasses breast surgery and the Monash BreastScreen program, has been named as the Principal Investigator of the MagSense™ study. Dr Fox is also a senior lecturer in the Monash University Department of Surgery and a senior leader of the multi-disciplinary team at the Monash Cancer Centre which includes medical imaging, medical oncology and radiation oncology.
Bob Proulx, Executive Chairman of Imagion Biosystems said, “We are delighted to be working with a leading healthcare organization and with Dr. Jane Fox, a highly regarded clinician who has dedicated her career to improving outcomes for patients with breast cancer and who is strongly supportive of the trial. After all the diligence and hard work, it is extremely exciting to be initiating our first clinical study.”
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited
Australian Media & Investor Relations
Kyahn Williamson, WE Communications
we-AUimagionbiosystems@we-worldwide.com
+61-401-018-828
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
The hydrogen batteries is the main product that brought me here. Kind of a round about success I would say. Looking good and hanging on
Or someone was conned into selling their shares?
Really low float Will fly like and eagle JMHO
IMO Hold on not a pump and dump You get rid of what you got you will be chasing it back up Something is brewing. They have so much in the works that it is hard to tell which one is causing this or which direction the company has chosen to go.
Always a smart a$$
There is the 911 signal Not long now
Mmmm N/A's gone
Looking at the GNCP box above with all the N/A's looks like they are getting ready for a name change MMMMMmmmm
IBX raises $6M in placement
Highlights:
$6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP.
Placement strongly supported by institutional investors.
Additional capital supports IBX development of the MagSense™ HER2 breast cancer test for a larger pivotal study including investing in manufacturing scale up.
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has raised $6M via a placement, at 8.5c per share.
The placement, led by Evolution Capital Advisors, was cornerstoned by four Australian-based institutional investors, and was met with very high demand.
The additional funds provide Imagion Biosystems with resources to accelerate its development plans and begin investing in manufacturing scale up of its nanoparticle technology. The company’s Phase I, first-in-human study, for HER2 metastatic breast cancer is on schedule to commence this calendar quarter.
“With our first-in-human study on track to commence this quarter, this fund raise supports advancing the next phase of product development and manufacturing scale up in parallel with the study rather than waiting until the study is complete,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “This approach will help shorten the timeline to commercial product.
“We are delighted by the high level of interest in IBX and the strength of support from investors for this placement.”
The Company will issue 76,538,864 shares (including 6 million options to the Lead manager) under Listing Rule 7.1, and 49,372 shares under Listing Rule 7.1A.
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion Biosystems Limited
Australian Media & Investor Relations
Kyahn Williamson, WE Communications
we-AUimagionbiosystems@we-worldwide.com
+61-401-018-828
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystem.com
This email was sent by Sam Sinclair, Imagion Biosystems, Level 25, 525 CollinsStreet, Melbourne, VIC 3000, Australia to ritten56@netscape.net
Thanks Rusty! Sounds really promising and hopeful for the sick
Like your way of thinking
I guess you didn't read the part that says they have reduced their expenses considerably.
NEWS: Over 30% gains for the last 14 reports Back log of orders. Have to wonder why no one posted this here.
https://finance.yahoo.com/news/growlife-inc-reports-increased-backlog-162200771.html
More News:
Click here for the accessible version
Manhattan Scientifics Nano Metal Technology Featured in New Research Paper
Thu, Nov 12, 2020 7:30 am
Manhattan Scientifics, Inc. (MHTX) (info@mhtx.com)To:you Details
MHTX's Nano Metal Technology Featured in New Research Paper “Implications on Improving Longevity of Medical Devices”
Manhattan Scientifics Inc., announces that University of New Mexico Tech Biology professor Dr. Rebecca Reiss has published new research that sheds light on how titanium implants interact with human tissue, potentially paving the way for a new generation of medical inserts that last longer.
The main thrust of this new research is that the smaller grain size of the titanium used in medical implants promotes growth of cells. They are specifically looking at how preosteoblast cells – or bone forming cells – grow when in contact with titanium.
“We’ve found that we get more cells that are bigger and healthier on ultra-fine grain titanium versus coarse grain”
Reiss said.
Read the Research Paper and Press Release Here
About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies.
Contacts
Manhattan Scientifics, Inc.
Manny Tsoupanarias, 917-688-4158
Manny@mhtx.com
Or
Marvin Maslow, 917-923-3300
Marvin@mhtx.com
For more information and all our press releases, please visit:
Manhattan Scientifics, Inc. | Imagion Biosystems
Website
Facebook
Copyright © 2020 Manhattan Scientifics, Inc., All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
Manhattan Scientifics, Inc.
244 5th Ave Ste 2341
New York, NY 10001-7604
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Email Marketing Powered by Mailchimp
Reply Reply All Forward
I think you have to make that request directly to them to get it done. Telling us will do no good. You have to approve it. Sorry
Your welcome
News: If you haven't already seen it: https://finance.yahoo.com/news/manhattan-scientifics-features-early-cancer-140000191.html
I agree!
Thanks Rusty
post 119712
Thats not a Cannabis company and is a lighting holding company
NEWS
Imagion Biosystems appoints Geoff Hollis as CFO
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the Company moves into its next phase of growth to develop and commercialize its medical device technology to non-invasively detect cancer.
Geoff, based in Melbourne, takes up his position as Imagion CFO on 1 December 2020.
Geoff has served as the Chief Financial Officer for multiple ASX listed companies, including Lifestyle Communities where he played a key role in cash management and financing to facilitate rapid growth, reaching the ASX300 and creating significant shareholder value. Geoff’s career in finance began with 10 years at Pitcher Partners a top ten national accounting and financial advisory firm.
Imagion’s executive chairman and CEO, Bob Proulx, said Geoff is a welcome addition to Imagion’s
executive management team. Being based in Australia, Geoff will be well positioned to assist with the Company’s developing business interests in Australia and will be closer to the Company’s investors and the capital markets to facilitate investor relations.
“We look forward to having Geoff aboard as the Company moves through its next growth phase and as we plan to advance the business beyond our upcoming MagSense™ HER2 Phase I study for metastatic breast cancer,” Mr Proulx said.
“Geoff has had great experience in corporate transformation, growth strategies, capital raising, capital management, attracting institutional investors and general investor relations. We expect that will be of significant benefit to Imagion as we enter an exciting phase of our business and work to maximise shareholder value.”
Geoff replaces Brian Conn, who served as Imagion’s part-time CFO since 2017 and who left Imagion in August to take up a full-time CFO position with another of his clients.
Not getting my shares. Not enough to go around
What a wild swing Not much room here for controlling Maybe they are looking for stops?
News
IMAGION ANNOUNCES HREC APPROVAL FOR
PHASE I STUDY
MELBOURNE — Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense™ HER2 Phase I study for metastatic breast cancer. With the study now approved the Company can proceed with finalising contracts with individual study sites.
Additionally, the Company reports that manufacturing of the MagSense™ HER2 nanoparticle formulation for the study remains on track, having successfully completed bulk batch production. The company expects to complete the final step of Good Manufacturing Practice (GMP) compliant packaging of the material on time to support the start of the study.
Imagion Biosystems Executive Chairman Bob Proulx said, “We are very pleased with our progress and will now be working diligently with our planned study sites to commence the study this calendar quarter as we have previously advised.”
ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.
Australian Media & Investor Relations
Kyahn Williamson, WE Communications
we-AUimagionbiosystems@we-worldwide.com
+61-401-018-828
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystem.com
This email was sent by Sam Sinclair, Imagion Biosystems, Level 25, 525 CollinsStreet, Melbourne, VIC 3000, Australia to ritten56@netscape.net
Unsubscribe
PDIV up 300%
NEWS
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer advises that it has today lodged an Appendix 3G for the issue of 10,150,000 Unlisted Performance Options.
Following the approval of the Equity Incentive Plan at the company’s Annual General Meeting held on 29 July 2020, the Board of Directors has approved the issuance of Unlisted Performance Options to employees of Imagion Biosystems, excluding the CEO, who are eligible to participate in the company’s incentive scheme.
The options have an exercise price of $0.0909 per share vesting over three years with expiry dates between 30 September 2025 to 31 August 2028.
-ENDS-
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.
Australian Media & Investor Relations
Kyahn Williamson, WE Communications
we-AUimagionbiosystems@we-worldwide.com
+61-401-018-828
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystem.com
Image
Issue of unlisted performance options under Equity Incentive Plan
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer advises that it has today lodged an Appendix 3G for the issue of 10,150,000 Unlisted Performance Options.
Following the approval of the Equity Incentive Plan at the company’s Annual General Meeting held on 29 July 2020, the Board of Directors has approved the issuance of Unlisted Performance Options to employees of Imagion Biosystems, excluding the CEO, who are eligible to participate in the company’s incentive scheme.
The options have an exercise price of $0.0909 per share vesting over three years with expiry dates between 30 September 2025 to 31 August 2028.
-ENDS-
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.
Australian Media & Investor Relations
Kyahn Williamson, WE Communications
we-AUimagionbiosystems@we-worldwide.com
+61-401-018-828
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystem.com
This email was sent by Sam Sinclair, Imagion Biosystems, Level 25, 525 CollinsStreet, Melbourne, VIC 3000, Australia to ritten56@netscape.net
Unsubscribe
Market down 400 points before it opens. The Trump covid thing is spooking the foreigners
Things that make you want to go Mmmm
https://apple.news/AR6K1-YWDSDuHeA_-58xJmg
I have to wonder if this is the same blockchain technology we have been talking about here. https://apple.news/AB2Ib5lE8RpOFI4AvPofBjw
Thats what I thought